V-Bio Ventures warns AI drug-discovery valuations outpace clinical evidence
XLV•V-Bio Ventures warned that AI drug-discovery valuations may be outpacing clinical evidence, citing Isomorphic Labs’ reported $10 billion to $17 billion valuation in May 2026 and rumors of a later $40 billion to $50 billion fundraising valuation. Roughly nine in 10 drug candidates entering clinical trials fail.
1. Valuations and evidence
V-Bio Ventures warned that AI drug-discovery valuations may be outpacing clinical evidence, echoing the genomics investment boom of 2000. Isomorphic Labs reached a reported $10 billion to $17 billion valuation in May 2026 without a clear product candidate; months later, rumors circulated of another fundraising round at a $40 billion to $50 billion valuation.
2. Clinical risks
Roughly nine in 10 drug candidates entering clinical trials fail, underscoring the gap between AI predictions and commercial medicines. V-Bio Ventures said private financing limits public scrutiny of valuations and advised anchoring pricing to future cash flows and clinical milestones.



